Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Polynovo ( (AU:PNV) ) has issued an announcement.
PolyNovo has disclosed a change in director Andrew Lumsden’s indirect shareholding, with his interest held via the Lumsden Family Trust increasing through an on-market purchase. The transaction involved acquiring 100,000 fully paid ordinary shares at an average price of $0.9136 per share, lifting his total indirect holding to 200,000 shares and signaling increased personal financial exposure to the company’s performance.
The acquisition was conducted as an on-market trade and did not involve any concurrent changes in derivative contracts or other securities-related agreements. This increase in director ownership may be interpreted by investors as a show of confidence in PolyNovo’s outlook, although no explicit commentary on strategic intentions or operational changes accompanied the disclosure.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.80 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited is a medical technology company that develops and manufactures implantable biomedical devices, with a focus on advanced wound care and tissue regeneration products. Its primary offerings are used in surgical and reconstructive procedures, targeting hospitals, clinics, and specialist surgeons in markets where high-performance wound management solutions are in demand.
Average Trading Volume: 2,104,442
Technical Sentiment Signal: Sell
Current Market Cap: A$642.5M
Find detailed analytics on PNV stock on TipRanks’ Stock Analysis page.